Oncolytics Biotech Inc.

Historical 13F Holders

Symbol
ONCY
CUSIP
682310875
All holders as of
Q2 2026
Type
Equity
Class
COM NEW
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 682310875 since 12/18/2024, newest first.

Filer % of Class Filed
Anson Funds Management LP 13G/A Amendment 1
7.0% 11/14/2025
Event 9/30/2025
Anson Funds Management LP 13G
9.6% 2/14/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q2 1 13.3 k $12.6 k
2026 Q1 57 3.00 M $2.61 M
2025 Q4 61 2.80 M $2.45 M
2025 Q3 57 2.84 M $3.79 M
2025 Q2 57 1.57 M $1.21 M
2025 Q1 52 1.38 M $756 k
2024 Q4 48 1.31 M $1.21 M
2024 Q3 43 1.20 M $201 M
2024 Q2 43 1.45 M $1.43 M
2024 Q1 40 2.12 M $2.25 M
2023 Q4 47 5.39 M $7.27 M
2023 Q3 34 6.22 M $13.6 M
2023 Q2 34 814 k $2.11 M
2023 Q1 34 1.14 M $1.38 M
2022 Q4 36 903 k $1.49 M
2022 Q3 37 717 k $887 k
2022 Q2 43 914 k $916 k
2022 Q1 44 709 k $1.12 M
2021 Q4 47 1.22 M $1.71 M
2021 Q3 38 1.05 M $2.79 M
2021 Q2 45 1.06 M $3.39 M
2021 Q1 42 1.06 M $3.87 M
2020 Q4 37 1.09 M $2.59 M
2020 Q3 37 814 k $1.46 M
2020 Q2 36 831 k $1.57 M
2020 Q1 34 597 k $823 k
2019 Q4 29 404 k $1.86 M
2019 Q3 22 396 k $225 k
2019 Q2 21 576 k $981 k
2019 Q1 23 195 k $360 k
2018 Q4 22 158 k $284 k
2018 Q3 24 203 k $768 k
2018 Q2 21 589 k $3.23 M